|
CN107252489A
(zh)
|
2009-04-13 |
2017-10-17 |
法国健康和医学研究院 |
Hpv颗粒及其用途
|
|
EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
|
EP3046583B1
(en)
|
2013-09-18 |
2019-02-13 |
Aura Biosciences, Inc. |
Virus-like particle conjugates for treatment of tumors
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
MX373687B
(es)
|
2013-11-21 |
2020-07-07 |
Ucl Business Ltd |
Célula natural (nk)
|
|
CA2932424C
(en)
*
|
2013-12-06 |
2023-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
|
NZ759969A
(en)
|
2013-12-20 |
2022-12-23 |
Fred Hutchinson Cancer Center |
Tagged chimeric effector molecules and receptors thereof
|
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
US11982673B2
(en)
|
2014-03-05 |
2024-05-14 |
Autolus Limited |
Methods
|
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
US10611837B2
(en)
|
2014-04-10 |
2020-04-07 |
Seattle Children's Hospital |
Transgene genetic tags and methods of use
|
|
DK3143134T3
(da)
|
2014-05-15 |
2021-01-04 |
Nat Univ Singapore |
Modificerede, naturlige dræberceller og anvendelser deraf
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
KR20170032406A
(ko)
|
2014-07-15 |
2017-03-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 조작된 세포
|
|
GB201415347D0
(en)
*
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
|
CA2969384A1
(en)
*
|
2014-12-17 |
2016-06-23 |
Cellectis |
Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
|
|
PL3560953T3
(pl)
|
2014-12-24 |
2024-05-13 |
Autolus Limited |
Komórka
|
|
WO2016123143A1
(en)
*
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
|
BR112017013981A2
(pt)
|
2015-01-26 |
2018-01-02 |
Cellectis |
receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
|
|
KR102763121B1
(ko)
|
2015-02-06 |
2025-02-04 |
내셔널 유니버시티 오브 싱가포르 |
치료적 면역 세포의 효능의 향상 방법
|
|
JP7237449B2
(ja)
*
|
2015-02-27 |
2023-03-13 |
アイセル・ジーン・セラピューティクス・エルエルシー |
血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
JP6961490B2
(ja)
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
US10786549B2
(en)
|
2015-04-23 |
2020-09-29 |
Baylor College Of Medicine |
CD5 chimeric antigen receptor for adoptive T cell therapy
|
|
GB201507108D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507115D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507119D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
EP3288570A4
(en)
*
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
|
GB201507368D0
(en)
*
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
EP3842448A1
(en)
*
|
2015-05-15 |
2021-06-30 |
City of Hope |
Chimeric antigen receptor compositions
|
|
WO2016196388A1
(en)
*
|
2015-05-29 |
2016-12-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
GB201509413D0
(en)
|
2015-06-01 |
2015-07-15 |
Ucl Business Plc |
Fusion protein
|
|
EP3307876B1
(en)
*
|
2015-06-10 |
2023-09-13 |
ImmunityBio, Inc. |
Modified nk-92 cells for treating cancer
|
|
US11655452B2
(en)
|
2015-06-25 |
2023-05-23 |
Icell Gene Therapeutics Inc. |
Chimeric antigen receptors (CARs), compositions and methods of use thereof
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
HK1255161A1
(zh)
*
|
2015-07-15 |
2019-08-09 |
Juno Therapeutics, Inc. |
用於过继性细胞治疗的工程细胞
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
AU2016306209B2
(en)
|
2015-08-07 |
2023-07-06 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific CAR T-cells for solid tumor targeting
|
|
GB201514874D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
|
JP2018534264A
(ja)
|
2015-09-28 |
2018-11-22 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞
|
|
GB201518817D0
(en)
*
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Cell
|
|
JP2018532801A
(ja)
|
2015-10-30 |
2018-11-08 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
標的化がん療法
|
|
GB201519900D0
(en)
*
|
2015-11-11 |
2015-12-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
KR20180118175A
(ko)
*
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
WO2017193059A1
(en)
|
2016-05-06 |
2017-11-09 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
EP3458077A4
(en)
*
|
2016-05-17 |
2020-04-01 |
Chimera Bioengineering Inc. |
METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING
|
|
CN109562126A
(zh)
*
|
2016-06-24 |
2019-04-02 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
ES2981703T3
(es)
|
2016-09-02 |
2024-10-10 |
Lentigen Tech Inc |
Composiciones y métodos para tratar cáncer con DuoCars
|
|
CN107893052B
(zh)
*
|
2016-09-09 |
2023-11-03 |
科济生物医药（上海）有限公司 |
融合蛋白及其应用
|
|
WO2018064602A1
(en)
*
|
2016-09-30 |
2018-04-05 |
Baylor College Of Medicine |
Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
|
|
BR112019006781A2
(pt)
|
2016-10-07 |
2019-07-30 |
Novartis Ag |
receptores de antígeno quiméricos para o tratamento de câncer
|
|
JP2019535262A
(ja)
*
|
2016-11-11 |
2019-12-12 |
オートラス リミテッド |
キメラ抗原受容体
|
|
NZ752984A
(en)
|
2016-11-22 |
2026-03-27 |
Nat Univ Singapore |
Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
|
|
US11408005B2
(en)
|
2016-12-12 |
2022-08-09 |
Seattle Children's Hospital |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
CA3048648A1
(en)
*
|
2017-01-10 |
2018-07-19 |
The General Hospital Corporation |
T cells expressing a chimeric antigen receptor
|
|
CN110582509A
(zh)
*
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
BR112019019917A2
(pt)
|
2017-03-27 |
2020-04-22 |
Nat Univ Singapore |
receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
|
|
CA3056591A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
IL269986B2
(en)
|
2017-04-12 |
2024-06-01 |
Aura Biosciences Inc |
Targeted combination therapy
|
|
MX2019013514A
(es)
*
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
GB201707779D0
(en)
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
JP7132249B2
(ja)
*
|
2017-05-15 |
2022-09-06 |
オートラス リミテッド |
キメラ抗原受容体（ｃａｒ）を含む細胞
|
|
GB201707783D0
(en)
*
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
CA3287539A1
(en)
|
2017-06-21 |
2026-03-02 |
Icell Gene Therapeutics Llc |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
|
|
US20210130775A1
(en)
*
|
2017-08-02 |
2021-05-06 |
Autolus Limited |
Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
|
|
US20190038733A1
(en)
|
2017-08-10 |
2019-02-07 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
|
WO2019068007A1
(en)
|
2017-09-28 |
2019-04-04 |
Immpact-Bio Ltd. |
UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)
|
|
CN117721084A
(zh)
*
|
2017-10-12 |
2024-03-19 |
美商生物细胞基因治疗有限公司 |
靶向多种抗原的复合嵌合抗原受体（cCAR）及其组成和使用方法
|
|
GB201717524D0
(en)
|
2017-10-25 |
2017-12-06 |
Autolus Ltd |
Vectors
|
|
WO2019084273A1
(en)
|
2017-10-25 |
2019-05-02 |
Actinium Pharmaceuticals, Inc. |
METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES
|
|
PT3703750T
(pt)
|
2017-11-01 |
2025-01-17 |
Memorial Sloan Kettering Cancer Center |
Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
|
|
EP3749685A4
(en)
|
2018-02-09 |
2021-12-22 |
National University of Singapore |
ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
|
|
GB201803079D0
(en)
*
|
2018-02-26 |
2018-04-11 |
Autolus Ltd |
Cell
|
|
CA3091224A1
(en)
|
2018-03-12 |
2019-09-19 |
Nantkwest, Inc. |
Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
MX2020012028A
(es)
|
2018-05-11 |
2021-03-29 |
Crispr Therapeutics Ag |
Metodos y composiciones para tratar el cancer.
|
|
GB201807870D0
(en)
|
2018-05-15 |
2018-06-27 |
Autolus Ltd |
A CD79-specific chimeric antigen receptor
|
|
WO2019220109A1
(en)
|
2018-05-15 |
2019-11-21 |
Autolus Limited |
Chimeric antigen receptor
|
|
EP3784776A4
(en)
|
2018-05-23 |
2022-01-26 |
National University of Singapore |
Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
|
|
CN110615842B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含共刺激受体的嵌合抗原受体及应用
|
|
GB201813178D0
(en)
|
2018-08-13 |
2018-09-26 |
Autolus Ltd |
Cell
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
IL281428B2
(en)
|
2018-09-27 |
2024-10-01 |
Autolus Ltd |
Chimeric antigen receptor
|
|
EP3860642A1
(en)
|
2018-10-05 |
2021-08-11 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3632461A1
(en)
*
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3632460A1
(en)
*
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
WO2020070290A1
(en)
|
2018-10-05 |
2020-04-09 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
GB201816522D0
(en)
|
2018-10-10 |
2018-11-28 |
Autolus Ltd |
Methods and reagents for analysing nucleic acids from single cells
|
|
MA54078A
(fr)
|
2018-11-01 |
2021-09-15 |
Juno Therapeutics Inc |
Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
CA3120563A1
(en)
|
2018-11-26 |
2020-06-04 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
AU2019397033B2
(en)
|
2018-12-12 |
2023-06-29 |
Kite Pharma, Inc. |
Chimeric antigen receptors and CAR-T cells and methods of use
|
|
ES3051182T3
(en)
|
2019-01-23 |
2025-12-26 |
Miltenyi Biotec Bv & Co Kg |
A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
|
|
US20220145325A1
(en)
|
2019-03-08 |
2022-05-12 |
Autolus Limited |
Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
|
|
GB201903237D0
(en)
|
2019-03-08 |
2019-04-24 |
Autolus Ltd |
Method
|
|
TW202110873A
(zh)
|
2019-04-30 |
2021-03-16 |
美商聖堤生物科技股份有限公司 |
嵌合受體及其使用方法
|
|
SG11202111865UA
(en)
|
2019-05-01 |
2021-11-29 |
Pact Pharma Inc |
Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
|
|
CN114450395A
(zh)
*
|
2019-05-16 |
2022-05-06 |
华盛顿大学 |
Lockr介导的car t细胞募集
|
|
GB201909144D0
(en)
|
2019-06-25 |
2019-08-07 |
Autolus Ltd |
Culture medium
|
|
GB201910185D0
(en)
|
2019-07-16 |
2019-08-28 |
Autolus Ltd |
Method
|
|
WO2021009510A1
(en)
|
2019-07-16 |
2021-01-21 |
Autolus Limited |
Method for preconditioning a subject who is about to receive a t-cell therapy
|
|
JP2022546315A
(ja)
*
|
2019-08-20 |
2022-11-04 |
センティ バイオサイエンシズ インコーポレイテッド |
キメラ抑制性受容体
|
|
EP4025594A2
(en)
*
|
2019-09-05 |
2022-07-13 |
Migal Galilee Research Institute Ltd. |
Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells
|
|
EP4031583A4
(en)
*
|
2019-09-16 |
2023-11-15 |
Fred Hutchinson Cancer Center |
CHIMERIC RECEPTOR PROTEINS AND THEIR USES
|
|
EP4041893A4
(en)
*
|
2019-10-08 |
2023-08-30 |
Provincial Health Services Authority |
CHEMERACY CYTOKINE RECEPTORS
|
|
US20220411535A1
(en)
*
|
2019-11-26 |
2022-12-29 |
University Of Utah Research Foundation |
Compositions and methods for upregulating hla class i on tumor cells
|
|
EP4065157A1
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
CN115052887B
(zh)
*
|
2019-12-11 |
2026-03-31 |
A2生物治疗公司 |
基于lilrb1的嵌合抗原受体
|
|
WO2021156277A1
(en)
|
2020-02-04 |
2021-08-12 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
|
|
EP4107175A4
(en)
*
|
2020-02-20 |
2024-03-20 |
Senti Biosciences, Inc. |
ARCHITECTURES OF INHIBITORY CHIMERIC RECEPTORS
|
|
CN115298209A
(zh)
*
|
2020-02-20 |
2022-11-04 |
森迪生物科学公司 |
抑制性嵌合受体构造体
|
|
GB202007044D0
(en)
|
2020-05-13 |
2020-06-24 |
Autolus Ltd |
Method
|
|
US12286465B2
(en)
|
2020-05-28 |
2025-04-29 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
|
|
GB202008957D0
(en)
|
2020-06-12 |
2020-07-29 |
Autolus Ltd |
Culture medium
|
|
JP2023535371A
(ja)
|
2020-07-17 |
2023-08-17 |
シミュレックス インコーポレイテッド |
免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法
|
|
CA3188867A1
(en)
|
2020-08-20 |
2022-02-24 |
Xueyin Wang |
Compositions and methods for treating ceacam positive cancers
|
|
IL300500A
(en)
|
2020-08-20 |
2023-04-01 |
A2 Biotherapeutics Inc |
Preparations and methods for the treatment of mesothelin positive cancer
|
|
WO2022040444A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
JP2023540339A
(ja)
*
|
2020-09-04 |
2023-09-22 |
インパクト バイオ ユーエスエー インコーポレイテッド |
癌治療に使用するためのバイシストロン性阻害性キメラ抗原受容体（ｉＣＡＲ）／活性化キメラ抗原受容体（ａＣＡＲ）構築物
|
|
US20220090013A1
(en)
|
2020-09-21 |
2022-03-24 |
A2 Biotherapeutics, Inc. |
Engineering immune cells based on antigen levels
|
|
WO2022081975A1
(en)
*
|
2020-10-15 |
2022-04-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inhibition of natural killer cell receptors
|
|
WO2022096664A1
(en)
|
2020-11-09 |
2022-05-12 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
WO2022177979A1
(en)
|
2021-02-16 |
2022-08-25 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating her2 positive cancers
|
|
US12144827B2
(en)
|
2021-02-25 |
2024-11-19 |
Lyell Immunopharma, Inc. |
ROR1 targeting chimeric antigen receptor
|
|
WO2022251377A1
(en)
*
|
2021-05-26 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Inhibitory chimeric antigen receptor prevents on-target off-tumor effects of adoptive cell therapy
|
|
US20240336903A1
(en)
*
|
2021-08-19 |
2024-10-10 |
Shandong Boan Biotechnology Co., Ltd. |
Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway
|
|
GB202112923D0
(en)
|
2021-09-10 |
2021-10-27 |
Ucl Business Ltd |
Binding domain
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
US20260097122A1
(en)
|
2022-05-11 |
2026-04-09 |
Autolus Limited |
Cd19/c22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
|
|
GB202209920D0
(en)
|
2022-07-06 |
2022-08-17 |
Autolus Ltd |
Cell
|
|
WO2024078995A1
(en)
|
2022-10-15 |
2024-04-18 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
EP4520346A1
(en)
|
2023-09-06 |
2025-03-12 |
Gyncentrum Sp. z o.o. |
Cells, methods and systems for use in the treatment of a cancer with dual-car-t
|
|
GB202403564D0
(en)
|
2024-03-12 |
2024-04-24 |
Autolus Ltd |
Method
|
|
NL2037811B1
(en)
|
2024-05-29 |
2025-12-12 |
Univ Oslo |
Treatment for Cancer
|
|
NL2037929B1
(en)
|
2024-06-11 |
2026-01-12 |
Prinses Maxima Centrum Voor Kinderoncologie B V |
Brain Organoid
|